

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10530963	
	Filing Date		2005-06-21	
	First Named Inventor	Menachem Rubinstein		
	Art Unit	1633		
	Examiner Name	MARVICH, MARIA		
	Attorney Docket Number	057878-16		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10530963
Filing Date	2005-06-21
First Named Inventor	Menachem Rubinstein
Art Unit	1633
Examiner Name	MARVICH, MARIA
Attorney Docket Number	057878-16

1	SULLINGER BA, et al. "Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication." Cell. 1990 Nov 2;63(3):601-8.	<input type="checkbox"/>
2	VERES G, et al. "Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes." J Virol. 1996 Dec;70(12):8792-800.	<input type="checkbox"/>
3	VERMA IM, and Somia N. "Gene therapy -- promises, problems and prospects." Nature. 1997 Sep 18;389:239-42.	<input type="checkbox"/>
4	VOSS, D., et al., "The role of enhancers in the regulation of cell-type-specific transcriptional control." Trends Biochem. 11, 287-289 (1986).	<input type="checkbox"/>
5	WAGNER EF, et al. "The human beta-globin gene and a functional viral thymidine kinase gene in developing mice." Proc Natl Acad Sci U S A. 1981 Aug;78(8):5016-20.	<input type="checkbox"/>
6	WANG L, et al. "Sustained correction of bleeding disorder in hemophilia B mice by gene therapy." Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3906-10.	<input type="checkbox"/>
7	XIAO W, et al. "Adeno-associated virus as a vector for liver-directed gene therapy." J Virol. 1998 Dec;72(12):10222-6.	<input type="checkbox"/>
8	ZECCHINA G, et al. "Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants." J Hematother Stem Cell Res. 2001 Dec;10(6):769-76.	<input type="checkbox"/>
9	ZHOU C, et al. "Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes." Gene. 1994 Nov 4;149(1):33-9.	<input type="checkbox"/>
10	ZWIEBEL JA, et al. "High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors." Science. 1989 Jan 13;243:220-2.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10530963
Filing Date	2005-06-21
First Named Inventor	Menachem Rubinstein
Art Unit	1633
Examiner Name	MARVICH, MARIA
Attorney Docket Number	057878-16

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.